Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest...
Up To Date
Latest News
An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of...
For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The...
Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased...
Recipharm remains on track for growth. The Swedish CDMO is acquiring Italian injectable beta lactam expert...
Share
